Glaukos (NYSE:GKOS) said yesterday that it agreed to pay nearly $3 million plus milestones to acquire former subsidiary Dose Medical and its drug-delivery technology for treating retinal diseases.
Sam Clemente, Calif.-based Glaukos spun Dose out as a standalone company in 2010, but paid $26 million in July 2015 for Dose Medical’s glaucoma assets, including the cancellation of a $10.9 million debt and $15 million in cash. In April 2017 Glaukos acquired Dose Medical‘s intraocular pressure sensor system assets for $5.5 million in cash, plus $9.5 million contingent upon development, clinical and regulatory milestones.
Get the full story on our sister site, Drug Delivery Business News